Cargando…

Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain

The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Purves-Tyson, T D, Owens, S J, Rothmond, D A, Halliday, G M, Double, K L, Stevens, J, McCrossin, T, Shannon Weickert, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545725/
https://www.ncbi.nlm.nih.gov/pubmed/28094812
http://dx.doi.org/10.1038/tp.2016.257
_version_ 1783255476481294336
author Purves-Tyson, T D
Owens, S J
Rothmond, D A
Halliday, G M
Double, K L
Stevens, J
McCrossin, T
Shannon Weickert, C
author_facet Purves-Tyson, T D
Owens, S J
Rothmond, D A
Halliday, G M
Double, K L
Stevens, J
McCrossin, T
Shannon Weickert, C
author_sort Purves-Tyson, T D
collection PubMed
description The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes. Gene expression of 12 dopamine-related molecules was examined in post-mortem midbrain (28 antipsychotic-treated schizophrenia cases/29 controls) using quantitative PCR. TH and the synaptic dopamine transporter (DAT) proteins were examined in post-mortem midbrain (26 antipsychotic-treated schizophrenia cases per 27 controls) using immunoblotting. TH and aromatic acid decarboxylase (AADC) mRNA and TH protein were unchanged in the midbrain in schizophrenia compared with controls. Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. However, DAT protein was significantly increased in putatively treatment-resistant cases of schizophrenia compared to putatively treatment-responsive cases. Midbrain monoamine oxidase A (MAOA) mRNA was increased, whereas MAOB and catechol-O-methyl transferase mRNAs were unchanged in schizophrenia. We conclude that, whereas some mRNA changes are consistent with increased dopamine action (decreased DAT mRNA), others suggest reduced dopamine action (increased MAOA mRNA) in the midbrain in schizophrenia. Here, we identify a molecular signature of dopamine dysregulation in the midbrain in schizophrenia that mainly includes gene expression changes of molecules involved in dopamine synthesis and in regulating the time course of dopamine action.
format Online
Article
Text
id pubmed-5545725
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55457252017-08-07 Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain Purves-Tyson, T D Owens, S J Rothmond, D A Halliday, G M Double, K L Stevens, J McCrossin, T Shannon Weickert, C Transl Psychiatry Original Article The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes. Gene expression of 12 dopamine-related molecules was examined in post-mortem midbrain (28 antipsychotic-treated schizophrenia cases/29 controls) using quantitative PCR. TH and the synaptic dopamine transporter (DAT) proteins were examined in post-mortem midbrain (26 antipsychotic-treated schizophrenia cases per 27 controls) using immunoblotting. TH and aromatic acid decarboxylase (AADC) mRNA and TH protein were unchanged in the midbrain in schizophrenia compared with controls. Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. However, DAT protein was significantly increased in putatively treatment-resistant cases of schizophrenia compared to putatively treatment-responsive cases. Midbrain monoamine oxidase A (MAOA) mRNA was increased, whereas MAOB and catechol-O-methyl transferase mRNAs were unchanged in schizophrenia. We conclude that, whereas some mRNA changes are consistent with increased dopamine action (decreased DAT mRNA), others suggest reduced dopamine action (increased MAOA mRNA) in the midbrain in schizophrenia. Here, we identify a molecular signature of dopamine dysregulation in the midbrain in schizophrenia that mainly includes gene expression changes of molecules involved in dopamine synthesis and in regulating the time course of dopamine action. Nature Publishing Group 2017-01 2017-01-17 /pmc/articles/PMC5545725/ /pubmed/28094812 http://dx.doi.org/10.1038/tp.2016.257 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Purves-Tyson, T D
Owens, S J
Rothmond, D A
Halliday, G M
Double, K L
Stevens, J
McCrossin, T
Shannon Weickert, C
Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title_full Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title_fullStr Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title_full_unstemmed Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title_short Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
title_sort putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545725/
https://www.ncbi.nlm.nih.gov/pubmed/28094812
http://dx.doi.org/10.1038/tp.2016.257
work_keys_str_mv AT purvestysontd putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT owenssj putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT rothmondda putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT hallidaygm putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT doublekl putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT stevensj putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT mccrossint putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain
AT shannonweickertc putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain